Besides vaccines, mRNA technology is being explored for therapeutic applications in oncology, infectious diseases, genetic disorders, and other areas. This diversification expands the market potential. The mRNA vaccines and therapeutics market was projected to attain...
On July 8th, Moderna, Inc. and Mitsubishi Tanabe Pharma Corporation (MTPC) officially entered into a joint agreement to co-promote Moderna’s mRNA respiratory vaccine portfolio in Japan, alongside Moderna’s COVID-19 vaccine, Spikevax. Moderna’s Success Sparks...
GSK on Wednesday announced it is restructuring an existing collaboration agreement with German biotech CureVac, focusing on their investigational mRNA vaccines for influenza and COVID-19 while withdrawing from other infectious disease projects. Under the amended...
U.S. health officials announced Tuesday that the federal government will pay Moderna $176 million to speed development of a pandemic flu vaccine based on mRNA technology. Such a vaccine could be used to treat bird flu in people, as concern grows about H5N1 cases...
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, has entered a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases....
